ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

Shift Towards More Treatable AIDS Lymphomas Identified

July 25, 2003

ASCO Ends Early Distribution Of Abstracts To Halt “ASCO Effect” On Stock Market

January 24, 2003

In Brief: House Committee Approves Funding Boost For NIH; Michigan Centers Receive $15M Gift

July 28, 1995

Niederhuber Outlines NCI Grant Funding Policies for FY08.

February 8, 2008

Laertrile Clinical Study Provides Solid Evidence: It Is Useless

May 8, 1981

HHS Inquiry Triggers Sloppy Stories On Gallo’s Laboratory

July 21, 1989